Off-Patent Industry Must Become ‘Focal Point’ For Health Systems Post-COVID
Medicines For Europe And IGBA Set Out Policy Priorities At Athens Conference
Off-patent medicines must become the “focal point” of pharmaceutical policies across the world as health systems recover from the COVID-19 pandemic, Medicines for Europe and the IGBA have urged as they held their joint annual conference in Athens, Greece.
You may also be interested in...
The IGBA has appointed Vivian Frittelli as chair of the organization for 2022, taking over from Sudarshan Jain. It is Frittelli’s second time as chair of IGBA, having taken up the mantle the first time following its 2015 rebrand.
Current EU policy discourages the domestic manufacturing of essential medicines, say Medicines for Europe and the European Fine Chemicals Group. The associations have called for “immediate, robust and ambitious” policy change to drive manufacturing back home.
Sandoz’s Rebecca Guntern has been named as interim president of Medicines for Europe for a three-month term, after Teva’s Christoph Stoller stepped down at the end of his two-year tenure.